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Abstract
Background: Congenital cataracts affect 3–6 per 10,000 live births and represent one of the leading causes of
blindness in children. Congenital cataracts have a strong genetic component with high heterogeneity and
variability.
Case presentation: Analysis of whole exome sequencing data in a patient affected with congenital cataracts
identified a pathogenic deletion which was further defined by other techniques. A ~98-kb homozygous deletion of
6p24.3 involving the first three exons (two non-coding and one coding) of GCNT2 isoform A, the first exon (coding)
of GCNT2 isoform B, and part of the intergenic region between GCNT2 and TFAP2A was identified in the patient and
her brother while both parents were found to be heterozygous carriers of the deletion. The exact breakpoints were
identified and revealed the presence of Alu elements at both sides of the deletion, thus indicating Alu-mediated
non-homologous end-joining as the most plausible mechanism for this rearrangement. Recessive mutations in
GCNT2 are known to cause an adult i blood group phenotype with congenital cataracts in some cases. The GCNT2
gene has three differentially expressed transcripts, with GCNT2B being the only isoform associated with lens
function and GCNT2C being the only isoform expressed in red blood cells based on earlier studies; previously
reported mutations/deletions have either affected all three isoforms (causing blood group and cataract phenotype)
or the C isoform only (causing blood group phenotype only). Dominant mutations in TFAP2A are associated with
syndromic anophthalmia/microphthalmia and other ocular phenotypes as part of Branchio-Ocular-Facial-Syndrome
(BOFS). While the patients do not fit a diagnosis of BOFS, one sibling demonstrates mild overlap with the
phenotypic spectrum, and therefore an effect of this deletion on the function of TFAP2A cannot be ruled out.
Conclusions: To the best of our knowledge, this is the first case reported in which disruption of the GCNT2 gene
does not involve the C isoform. The congenital cataracts phenotype in the affected patients is consistent with the
previously defined isoform-specific roles of this gene. The GCNT2-TFAP2A region may be prone to rearrangements
through Alu-mediated non-homologous end-joining.
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Background
Congenital cataracts are diagnosed within the first year
of life. These cataracts are one of the leading causes of
blindness in children and are estimated to occur with a
prevalence of 3–6 per 10,000 live births [1]. Congenital
cataracts may appear either in isolation or in association
with other ocular or systemic anomalies. Up to 25 % of
congenital cataracts are thought to be caused by genetic
defects [2]. The genetic landscape of mutations causing
congenital cataract is extremely diverse; more than 40
genes and additional loci have been associated with non-
syndromic cataract [2–6].
GCNT2 (glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme) was first identified in 2001 as the
gene encoding for the glycosyltransferase responsible for
the human blood group I antigen. Recessive mutations
in GCNT2 result in an adult i blood group phenotype,
which is also associated with congenital cataracts in
some cases [7]. Alternative splicing of the GCNT2 gene
produces three transcripts (A, B, and C). The three tran-
scripts share a common second and third coding exon
with a unique first exon for each isoform; differing ex-
pression profiles were identified for the transcripts with
only the GCNT2B isoform expressed in lens epithelial
cells and only the GCNT2C isoform expressed in reticu-
locytes [8]. To date, seven missense mutations, one non-
sense mutation, and two large deletions have been
reported; mutations in exon 1C, affecting only the
GCNT2C isoform, cause the adult i blood group without
cataracts while mutations/deletions affecting exons 2
and 3, shared by all isoforms, result in the adult i blood
group along with congenital cataract [7–11].
Case presentation
Patient 1(individual II:1) is an 18-month old Pakistani
female affected with bilateral dense central congenital
cataract (Fig. 1a, Table 1) which were visually significant
and required extraction at 2 months of age, mild asym-
metry of the palpebral fissures, and left nasolacrimal
duct obstruction; her development is normal and growth
parameters are generally normal with the exception of
borderline microcephaly (length 83.8 cm, 75–90th
centile; weight 10.2 kg, 25–50th centile; and head
circumference 44 cm (3rd centile)). Physical exam at
4 months of age identified hypotelorism (familial) and
mildly widely-spaced nipples. Her younger brother, age
6 months, was similarly affected with visually significant
bilateral dense central congenital cataracts requiring
extraction around 2 months of age; his length (67.5 cm,
25–50th centile), weight (6.8 cm, 5–10th centile), and
head circumference (42.5 cm, 10–25th centile) are
all within the normal range (Table 1). Family history
shows unaffected second-cousin parents with additional
endogamous mating within the family. A double
second-cousin to the proband is affected with bilateral
non-syndromic anophthalmia/ microphthalmia with no
additional details available.
Materials and methods
Whole exome sequencing was performed by Macrogen
(previously Axeq) and analyzed as previously described
[12]; briefly, exome data from the proband was analyzed
using the SNP & Variation Suite (SVS; Golden Helix, Boze-
man, MT, USA) to identify/exclude mutations in the coding
and splicing regions of 40 known nonsyndromic cataract
genes and 7 additional crystallins [3–6]; synonymous vari-
ants and variants with a frequency of >1 % in the general
population (http://exac.broadinstitute.org, http://evs.gs.wa-
shington.edu/EVS/, http://www.1000genomes.org/) were
considered to be benign variants. Copy number variation
analysis was completed by screening exome sequencing
data using the Copy Number Inference From Exome Reads
(CoNIFER) v0.2.2 software package as previously outlined
[13]; regions of interest were further verified by independ-
ent quantitative PCR reactions using DNA samples from
the proband and other available familial samples with SYBR
Green PCR Master Mix (Applied Biosystems/Life Tech-
nologies, Carlsbad, CA, USA). qPCR reactions utilized
three region-specific probes (Additional file 1: Table S1)
and were performed as follows: primers located within re-
gions of interest were designed using Primer3Plus software
(http://sourceforge.net/projects/primer3/) using qPCR set-
tings. Each reaction was comprised of five nanograms of
DNA in a total reaction volume of 12uL. Each primer set
was run three times in triplicate using patient, parental or
control DNA on a Bio-Rad CFX Connect Real-Time PCR
Table 1 Phenotype and genotype information of the affected patients
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Borderline microcephaly (3rd centile), mild
asymmetry of the palpebral fissures, left






The first coding exons of GCNT2A and
GCNT2B, two 5’noncoding exons of
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The first coding exons of GCNT2A and
GCNT2B, two 5’noncoding exons of
GCNT2A, and a part of the region
upstream of TFAP2A
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machine (Bio-Rad, Hercules, CA, USA). A primer set for
the housekeeping gene RPPH1 (ribonuclease P RNA com-
ponent H1) was used to normalize all data. A probe located
in NDP (Norrie disease (pseudoglioma)), located on the X-
chromosome, was used as a copy-loss control. All experi-
ments included a no-template control and an unaffected
human DNA sample with presumably normal copy number
at each region for comparison. Copy number changes were
calculated using the 2-ΔΔCt method as previously described
[14]. Following qPCR confirmation, the size and exact
breakpoints of the deletion were determined using a series
of regular PCR reactions that utilized primers located on
both ends of the region (as defined by CoNIFER and qPCR
analysis) and standard conditions (Additional file 1: Table
S1). Since the patients were apparently homozygous for the
deletion, no amplification product indicated that the
primer(s) are located inside of the deleted region while the
presence of a PCR product indicated primers outside of the
deletion. Once sequences bordering the deleted region on
the centromeric and telomeric sides were determined, the
corresponding primers were used to amplify a 1.5 kb
region across the breakpoints. The resultant product
was cloned into pCRII-TOPO® (Life Technologies,
Carlsbad, CA, USA) vector using the manufacturer’s
protocols and sequenced bidirectionally with M13
forward and reverse primers using Big Dye Termin-
ator v3 chemistry and an ABI 3730XL sequencer
(Applied Biosystems/Life Technologies, Carlsbad, CA,
USA); the obtained sequences were compared with
the corresponding reference sequence using BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Results and discussion
Review of the whole exome sequencing (WES) data from
Patient 1 did not identify any potentially pathogenic
variants (with only two synonymous variants) in known
nonsyndromic cataract genes. The WES data was then
analyzed for copy number variation which revealed a
potential 208-kb deletion (6p24.3 chr6: 10,412,788-
10,621,660) affecting TFAP2A and GCNT2. The deletion
was verified using qPCR probes located in the first
coding exon of GCNT2 isoform A and the first exon of
TFAP2A; the qPCR confirmed deletion of the GCNT2
sequence in both unaffected parents (haploid, heterozy-
gous) and affected children (complete loss, homozygous)
while diploid copy of the TFAP2A sequence was
identified in all family members. Further analysis of
the region by a series of regular PCR reactions using
affected DNA identified the centromeric breakpoint
between chr6:10472330–10472606 (set 7; diploid) and
chr6:10474759–10474901 (set 8; complete loss) and the
telomeric breakpoint between chr6:10570580–10570905
(set 13, complete loss) and chr6:10571951–10572257 (set
14, diploid). Primer sets designed to span the deleted re-
gion produced a ~1.5 kb product from the DNA of the af-
fected patients. Sequencing of this product identified the
exact deletion breakpoint sites: their analysis revealed the
presence of Alu repeats and specifically a 12-bp identical
sequence at both sides of the deleted region of 97.974-kb
(hg19, chr6: 10,473,864–10,571,838) (Fig. 2). The homozy-
gous deletion encompassed four exons of GCNT2 (the first
two noncoding and one coding exons of isoform A and the
first coding exon of isoform B) and extended 47.471-kb
Fig. 1 Patient photographs and pedigree. a Photograph of Patient 1’s eyes at 2 months of age showing bilateral cataract. b Pedigree showing
both affected siblings with a homozygous deletion of 6p24.3 while the unaffected parents are heterozygous carriers. WT: wild type; black arrow
indicates proband
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upstream of the most 5’ exon of the GCNT2 gene (Fig. 2).
The distance from the telomeric end of the deletion to the
nearest protein-coding gene, TFAP2A (transcription factor
AP-2 alpha), is 54.300-kb. The distance from the centro-
meric end of the deletion to the fist exon of GCNT2
isoform C is 13.922-kb. Although GCNT2C and TFAP2A
were not included in the deletion, effects on their expres-
sion through possible interference with regulatory elements
cannot be ruled out.
Genomic deletions of GCNT2 have been previously re-
ported in two families with blood group i and congenital
cataracts but both deletions included exons 2 and 3
which are shared by all isoforms [7, 11]. Borck and col-
leagues noted that the GCNT2 locus is rich with Alu ele-
ments and therefore is likely a hotspot for deletions or
duplications to occur [11]. The GCNT2 gene has three
differentially expressed transcripts, with GCNT2B being
the only isoform associated with lens function and
GCNT2C being the only isoform expressed in red blood
cells [8]. The GCNT2 protein modifies the i antigen, a
linear sphingoglycolipid present on the cell surface of
most human cells as well as on glycoproteins in body
fluids, into the active branched I antigen; the i/I antigens
are thought to play a role in the regulation of cell growth
and differentiation in the developing lens [8, 9].
The deletion described in this case report differs from
previously reported deletions and mutations since it only
affects the GCNT2A and GCNT2B isoforms and leaves the
GCNT2C isoform intact. Previous studies demonstrated
that only the GCNT2B isoform is expressed in lens epithe-
lial cells and patients with mutations which specifically
affect the C isoform demonstrate the adult i phenotype
without congenital cataracts [8]. Thus, the presence of
cataract in the affected patients reported here with a clear
disruption of GCNT2A and B isoforms only is consistent
with the isoform-specific roles identified for this gene.
Additionally, in the case reported here we were able to
identify the exact sequences at the breakpoints and clearly
implicate Alu-mediated non-homologous end-joining as a
mechanism for this rearrangement. This mechanism has
been previously reported by our and other groups [15, 16]).
The deletion reported here also extends into the gen-
omic region upstream of GCNT2 and TFAP2A which
are positioned in a head-to-head orientation. TFAP2A is
approximately 100-kb distal to GCNT2 and the deletion
removes approximately 47-kb of genomic sequence
between the two genes. It is possible that this deletion
could affect TFAP2A function through removal/re-
arrangement of regulatory elements, as has been shown
for other genes [17–19]. TFAP2A is a retinoic acid
responsive transcription factor which is required for
normal development of the lens and optic cup as well as
for parts of the craniofacial region. Heterozygous muta-
tions in TFAP2A cause Branchio-Ocular-Facial-Syn-
drome (BOFS) characterized by craniofacial phenotypes
(distinct facial features, microcephaly, and cleft lip/pal-
ate), skin defects in the cervical region or regions around
the ear, ocular defects (microphthalmia, coloboma, stra-
bismus, cataract, or ptosis), lacrimal duct obstruction,
and hearing loss [20–22]. Missense mutations account
for the majority of TFAP2A variants, however whole
gene deletions have also been reported. To date, no dele-
tions affecting the upstream region of TFAP2A, but not
the coding region itself, have been reported. Careful
physical examination of the patients did not identify suf-
ficient features to warrant a diagnosis of BOFS in the
siblings, but Patient 1 did show borderline microcephaly,
mild asymmetry of the palpebral fissures, left nasolacri-
mal duct obstruction, and somewhat widely spaced nip-
ples. While the shared cataract phenotype observed in
the affected siblings is consistent with the GCNT2 defi-
ciency alone, an effect of this deletion on the function of
TFAP2A and the observed phenotypes cannot be com-
pletely ruled out. Interestingly, a double second-cousin
Fig. 2 Schematic presentation of the chromosome 6p24.3−24.2 region and the identified deletion. The UCSC Genome Browser (http://
genome.ucsc.edu) view of the deleted region indicating the positions of genes is included; the deletion identified in the affected family is shown
as a rectangular red box; the DNA sequence across the breakpoint for the deleted allele is shown at the bottom of the drawing with regions
corresponding to the telomeric and centromeric flanks of the deletion indicated by dashed lines and a 12-nt repeat highlighted in red font
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to the proband has been reported to be affected with
bilateral anophthalmia/ microphthalmia (A/M), an ocu-
lar condition that is more consistent with the TFAP2A
spectrum. It is possible that the familial deletion ex-
panded to include TFAP2A in this patient; alternatively,
the A/M diagnosis may have an independent genetic
etiology. Unfortunately, no other familial samples were
available for further study.
Conclusions
We identified a ~98-kb homozygous deletion involving
several exons of GCNT2 and the region upstream of
TFAP2A in two children affected with congenital cata-
racts from a consanguineous family of Pakistani decent.
This cataract-causing deletion removes the first coding
exons of GCNT2 isoforms A and B but leaves the
GCNT2C sequence intact, providing further support for
the isoform-specific roles of this gene; this is the first
disruption of GCNT2 reported which does not affect
isoform C. While the patients do not fit a diagnosis of
BOFS, one sibling demonstrates mild overlap with the
phenotypic spectrum, and therefore an effect of this
deletion on the function of TFAP2A cannot be ruled out.
Additional file
Additional file 1: Table S1. Summary of PCR/qPCR reactions and copy
number status in the affected family. (DOCX 21 kb)
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